AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial
- 1 May 1989
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 72 (1) , 45-53
- https://doi.org/10.1111/j.1365-2141.1989.tb07650.x
Abstract
The outcome of treatment with strand first line therapy of 66 patients with acute myeloid leukaemia (AML) secondary to preceding chemotherapy (Group 1), a myelodysplastic state (Group 2) or a myeloproliferative disorder (Group 3) was analyzed in relation to the preceding disorder, the cytogenetic pattern where available, and the cytology and cytochemistry of blood and bone marrow. The complete remission (CR) rate for the secondary AMLs was 36% (24/66), with 24% (16/66) dying in the induction period and 39% (26/66) having resistant disease. The CR rate was 25% (5/20) for Group 1, 42% (15/36) for Group 2, and 40% (4/10) for Group 3. Even after allowance for the generally older age of the secondary AML patients, they still had a significantly poorer CR rate than the de novo AMLs (P = 0.0004). The lower CR rate was chiefly due to resistant disease. Despite this, overall survival was not significantly worse for the secondary AML patients (P = 0.15). For the 36% that achieved remission, remission duration appeared similar to that of de novo cases. Of 62 cases with adequate cytology, 38 (61%) had evidence of erythroid and/or megakaryocytic dysplasia with a CR rate of 32% (12/38). The CR rate of these multineage leukaemias was not significantly different from that of the 24 (39%) who showed granulcoyte/monocyte precursor involvement only, 42% (10) of whom achieved CR. The presence of features of differentiation within blast cells such as Auer rods or sudanophilia (> 50% positive blasts) was associated with a higher remission rate 47% (18/38) than that of poorly differentiated cases 17% (3/18) (P = 0.04) and thus appeared to be a more important determinant of Cr achievement than was lineage involvement. Cases with a normal karyotype had a 33% (7/21) CR rate, while those with chromosomal abnormalities had a 37% (9/24) CR rate. Only 12 of the 45 cases with adequate cytogenetic analysis showed deletions or monosomies involving chromosomes 5 or 7, and seven of these were in Group 1.This publication has 25 references indexed in Scilit:
- Clinical and laboratory features of de novo acute myeloid leukaemia with trilineage myelodysplasiaBritish Journal of Haematology, 1987
- Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features.Journal of Clinical Oncology, 1986
- PRINCIPAL RESULTS OF THE MEDICAL RESEARCH COUNCIL'S 8th ACUTE MYELOID LEUKAEMIA TRIALThe Lancet, 1986
- The association of specific “favorable” cytogenetic abnormalities with secondary leukemiaCancer, 1986
- Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7.Journal of Clinical Oncology, 1986
- Chromosome analysis of 63 cases of secondary nonlymphoid blood disorders: A cooperative studyCancer Genetics and Cytogenetics, 1984
- Therapy of Secondary Acute Nonlymphocytic Leukemia with CytarabineNew England Journal of Medicine, 1983
- Acute myeloid leukemia following treatment of hodgkin's disease. A reviewCancer, 1982
- Therapy-related leukemia. A panmyelosisCancer, 1979
- Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative GroupBritish Journal of Haematology, 1976